Introduction
Telithromycin (HMR 3647) is a new ketolide antibacterial agent synthesized by chemical modification of erythromycin A. Many investigations have demonstrated that telithromycin shows good in vitro antibacterial activity against Gram-positive bacteria, including erythromycin A-resistant isolates of Streptococcus pneumoniae, an organism important in the aetiology of community-acquired respiratory tract infections. 1, 2 A recent survey shows that the rate of pneumococcal resistance to erythromycin A is high (36.3%) in Japan.
MBC was determined by subculture of 10 L of broth from each well without visible growth on brain-heart infusion agar (Difco) plates for S. aureus, and blood agar plates for S. pneumoniae and Enterococcus faecalis, and was defined as the lowest concentration of each drug that exhibited Ͼ99.9% reduction in growth.
DNA isolation and detection of ermB and mef (mefA or mefE) genes
Genomic DNA was extracted according to the instructions provided with SepaGene (Sanko junyaku Co., Tokyo, Japan). Macrolide-resistance genes were detected by the PCR method as described by Sutcliffe et al. 7 Strain 3585 (ermB) and strain 02J1175 (mefE), kindly provided by Dr Joyce de Azavedo, University of Toronto, were used as positive controls. It has been reported that the mefA and mefE genes mediate resistance by excretion of the drug, while ermB gene resistance is due to the presence of a 50S ribosome subunit mutation. 7, 8 A further distinction of mef genes into mefA and mefE was not possible with the methodology used.
Results and discussion
The 100 isolates of S. pneumoniae included 32 erythromycin A-susceptible isolates and 67 erythromycin Aresistant isolates (Table I ). In addition, the erythromycin A-resistant isolates included two isolates that possessed both the mef and ermB resistance genes, 32 isolates that possessed only the mef genes and 33 isolates that possessed only the ermB gene. The MIC 90 of telithromycin was 0.125 mg/L for isolates carrying either of these resistance genes, although this value was 16 times higher than that (0.008 mg/L) for the erythromycin A-susceptible isolates. The MIC 90 s of erythromycin A, clarithromycin and azithromycin were 2-4 mg/L for erythromycin A-resistant S. pneumoniae with only the mef genes and Ͼ128 mg/L for S. pneumoniae with only the ermB gene. The potent activity of telithromycin compared with that of the macrolides tested could be related either to the affinity of the drug for methylated ribosome and/or to a lack of capacity to produce inducible resistance. 9 Nishijima et al. 10 reported recently that almost all ermB ϩ -mediated resistance was inducible and resistance in mef ϩ isolates was non-inducible. Therefore, the activity of telithromycin against ermB ϩ isolates might be associated with its poor activity as an inducer, and against mef ϩ isolates due to the high affinity of telithromycin for the target ribosome. The MIC 90 s of amoxycillin, cefdinir and levofloxacin for the erythromycin A-resistant S. pneumoniae isolates were 8-128 times higher than that of telithromycin.
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Erythromycin A-resistant isolates of Streptococcus pyogenes and Streptococcus agalactiae were not available for this study (Table I) . Telithromycin showed excellent antibacterial activity against both isolates, with MIC 90 s of 0.008-0.016 mg/L and these activities were 2-16 times greater than those of the reference compounds tested.
Telithromycin had excellent antibacterial activity against erythromycin A-susceptible and inducible erythromycin A-resistant S. aureus with an MIC 90 of 0.125 mg/L (Table  I) . These activities were greater than those of the reference compounds. However, telithromycin, in common with the macrolides tested, exhibited little activity against the S. aureus isolates with constitutive erythromycin A resistance. Against Staphylococcus epidermidis, the antibacterial activity of telithromycin was similar to that against S. aureus (data not shown).
Telithromycin was much more potent against enterococcal isolates than the reference compounds tested (Table I) . In particular, the MIC 90 of telithromycin was р0.063 mg/L for erythromycin A-susceptible and intermediate E. faecalis. In addition, telithromycin showed activity, even against erythromycin A-resistant E. faecalis, which was у32 times greater than those of the macrolides tested. Telithromycin was the most potent antibacterial agent against E. faecium among the compounds tested.
Telithromycin showed bactericidal activity against not only erythromycin A-susceptible isolates of S. pneumoniae, but also erythromycin A-resistant isolates that possessed only the mef genes. The MBC 90 /MIC 90 ratio for those isolates was 1 (Table II) . However, against erythromycin A-resistant S. pneumoniae isolates that possessed the ermB gene, the MBC 90 /MIC 90 ratio of telithromycin was 4. This result suggests that 50S ribosome mutation rather than 800 excretion of the drug might influence the bactericidal activity of this compound. MBC 90 /MIC 90 ratios of telithromycin for erythromycin A-susceptible and for inducible erythromycin A-resistant S. aureus were 16 and 8, respectively (Table II) . Against the E. faecalis isolates, telithromycin showed an MBC 90 /MIC 90 ratio of 4 for the erythromycin A-intermediate isolates, whereas the ratio for the erythromycin A-resistant isolates was 32. These differences in antibacterial and/or bactericidal activities of telithromycin against Gram-positive cocci according to the species might be influenced by the binding of telithromycin to the target site. Amoxycillin, cefdinir and levofloxacin showed bactericidal activity against bacterial isolates tested in this study.
These data, in general, show close agreement with the results that have already been reported for in vitro antibacterial activity of telithromycin against clinical isolates in various geographical regions of the world.
